EZH2 expression showed significant prognostic impact in melanoma, prostate, and endometrial carcinoma in univariate survival analyses, but revealed independent multivariate prognostic importance only in carcinoma of the endometrium and prostate [17]. Here, EZH2 is linked to endometrial carcinoma.